DOMA Perpetual Capital Management sent a letter to the Board of Directors of Pacira Biosciences urging the Board to accelerate and increase its stock repurchase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira price target raised to $18 from $15 at Jefferies
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Largest borrow rate increases among liquid names
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Warner Bros. downgraded, Starbucks upgraded: Wall Street’s top analyst calls